☰

Shaun P. Rosebeck, Ph.D. - Publications

Affiliations: 
2006 The University of Toledo 
Area:
Cell Biology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Stefka AT, Johnson D, Rosebeck S, Park JH, Nakamura Y, Jakubowiak AJ. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Medicine. PMID 31714026 DOI: 10.1002/Cam4.2695  0.398
2019 Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. British Journal of Haematology. PMID 31124580 DOI: 10.1111/Bjh.15969  0.329
2017 Jakubowiak AJ, Raje N, Vij R, Reece D, Berdeja JG, Stephens L, Tinari KM, Rosenbaum CA, Jasielec JK, Richardson PG, Gurbuxani S, Nam J, Severson E, McIver A, Wolfe B, ... ... Rosebeck S, et al. High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial Blood. 130: 4533-4533. DOI: 10.1182/Blood.V130.Suppl_1.4533.4533  0.303
2016 Jakubowiak A, Jasielec J, Rosenbaum CA, Cole CE, Chari A, Nam J, Severson E, Stephens LA, McDonnell K, Rosebeck S, Zimmerman T, Karrison T, Zonder J. Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Blood. 128: 973-973. DOI: 10.1182/Blood.V128.22.973.973  0.326
2016 Zimmerman T, Raje NS, Vij R, Reece D, Berdeja JG, Stephens LA, McDonnell K, Rosenbaum CA, Jasielec J, Richardson PG, Gurbuxani S, Nam J, Severson E, Wolfe BD, Rosebeck S, et al. Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Blood. 128: 675-675. DOI: 10.1182/Blood.V128.22.675.675  0.323
2015 Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum S, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase 10-dependent Apoptosis by Carfilzomib and Selinexor. Molecular Cancer Therapeutics. PMID 26637366 DOI: 10.1158/1535-7163.Mct-15-0488  0.455
2015 Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, Ngoka L, Jasielec J, Richardson PG, Volchenboum S, Nesvizhskii AI, Sreekumar A, Jakubowiak AJ. Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. British Journal of Haematology. 170: 66-79. PMID 25824111 DOI: 10.1111/Bjh.13394  0.393
2015 Zimmerman TM, Griffith KA, Jasielec J, Rosenbaum CA, McDonnell K, Waite-Marin J, Berdeja JG, Raje NS, Reece DE, Vij R, Alonge M, Rosebeck S, Gurbuxani S, Faham M, Kong KA, et al. Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). Journal of Clinical Oncology. 33: 8510-8510. DOI: 10.1200/Jco.2015.33.15_Suppl.8510  0.325
2015 Jakubowiak A, Jasielec J, Rosenbaum CA, Zonder JA, Cole CE, Chari A, Nam J, Stephens LA, McDonnell K, Uribe R, Rosebeck S, Rashal T, Youssoufian H, Henry S, Shacham S, et al. Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM) Blood. 126: 4223-4223. DOI: 10.1182/Blood.V126.23.4223.4223  0.331
2014 Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM. The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling. Oncogene. 33: 2520-30. PMID 23770847 DOI: 10.1038/Onc.2013.195  0.334
2014 Rosebeck S, Alonge M, Jasielec J, Mayampurath A, Volchenboum SL, Shacham S, Kauffman M, Jakubowiak A. Gene Expression and Transcription Factor (TF) Activation Profiling Identifies Suppression of Multiple Myeloma (MM) Cell Survival and Chemoresistance Pathways By Inhibition of XPO1/CRM1-Dependent Nuclear Export with Selinexor Blood. 124: 3444-3444. DOI: 10.1182/Blood.V124.21.3444.3444  0.383
2014 Rosebeck S, Alonge M, Jasielec J, McCauley D, Shacham S, Kauffman M, Jakubowiak A. Anti-Myeloma Activity of Combined Inhibition of the Proteasome with Carfilzomib (CFZ) and XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330) Via a Novel Mechanism of Intracellular Activation of Caspase 10-Dependent Apoptosis Blood. 124: 3443-3443. DOI: 10.1182/Blood.V124.21.3443.3443  0.458
2014 Vliet Mv, Jasielec J, Dytfeld D, Vij R, Dumee B, Bosman L, deBest LCM, Alonge M, Rosebeck S, Kandarpa M, McDonnell K, Griffith KA, Beers EHv, Jakubowiak A. Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Blood. 124: 2141-2141. DOI: 10.1182/Blood.V124.21.2141.2141  0.3
2014 Jasielec J, Dytfeld D, Griffith KA, McDonnell K, Lebovic D, Kandarpa M, Anderson T, Mietzel M, Faham M, Lee L, Levy J, Alonge M, Rosebeck S, Kaminski M, Jakubowiak A. Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd) Blood. 124: 2127-2127. DOI: 10.1182/Blood.V124.21.2127.2127  0.314
2013 Jasielec J, Dytfeld D, Griffith KA, McDonnell K, Lebovic D, Kandarpa M, Vesole DH, Jagannath S, Mietzel MA, Vij R, Faham M, Lee L, Beers EHv, Vliet MHv, Levy J, ... ... Rosebeck S, et al. Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM) Blood. 122: 3220-3220. DOI: 10.1182/Blood.V122.21.3220.3220  0.311
2013 Rosebeck S, Kandarpa M, Alonge MM, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ. Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM) Blood. 122: 279-279. DOI: 10.1182/Blood.V122.21.279.279  0.479
2011 Rosebeck S, Rehman AO, Lucas PC, McAllister-Lucas LM. From MALT lymphoma to the CBM signalosome: three decades of discovery. Cell Cycle (Georgetown, Tex.). 10: 2485-96. PMID 21750409 DOI: 10.4161/Cc.10.15.16923  0.315
2011 Rosebeck S, Sudini K, Chen T, Leaman DW. Involvement of Noxa in mediating cellular ER stress responses to lytic virus infection. Virology. 417: 293-303. PMID 21742363 DOI: 10.1016/J.Virol.2011.06.010  0.533
2011 Rosebeck S, Lucas PC, McAllister-Lucas LM. Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncology (London, England). 7: 613-7. PMID 21568677 DOI: 10.2217/Fon.11.35  0.304
2011 Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science (New York, N.Y.). 331: 468-72. PMID 21273489 DOI: 10.1126/Science.1198946  0.339
2008 Rosebeck S, Leaman DW. Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a. Apoptosis : An International Journal On Programmed Cell Death. 13: 562-72. PMID 18330707 DOI: 10.1007/S10495-008-0190-0  0.594
Show low-probability matches.